Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Myriad Genetics (MYGN) over the last 16 years, with Q3 2025 value amounting to $148.0 million.

  • Myriad Genetics' Total Current Liabilities fell 408.3% to $148.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $148.0 million, marking a year-over-year decrease of 408.3%. This contributed to the annual value of $164.1 million for FY2024, which is 525.98% up from last year.
  • Myriad Genetics' Total Current Liabilities amounted to $148.0 million in Q3 2025, which was down 408.3% from $199.9 million recorded in Q2 2025.
  • Myriad Genetics' 5-year Total Current Liabilities high stood at $271.0 million for Q2 2021, and its period low was $119.7 million during Q2 2022.
  • Its 5-year average for Total Current Liabilities is $169.6 million, with a median of $154.3 million in 2024.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first crashed by 5583.03% in 2022, then soared by 8471.18% in 2023.
  • Over the past 5 years, Myriad Genetics' Total Current Liabilities (Quarter) stood at $204.3 million in 2021, then plummeted by 32.84% to $137.2 million in 2022, then rose by 13.63% to $155.9 million in 2023, then rose by 5.26% to $164.1 million in 2024, then fell by 9.81% to $148.0 million in 2025.
  • Its last three reported values are $148.0 million in Q3 2025, $199.9 million for Q2 2025, and $151.1 million during Q1 2025.